Vaccines against Middle East respiratory syndrome coronavirus for humans and camels
- PMID: 27786402
- PMCID: PMC7169231
- DOI: 10.1002/rmv.1917
Vaccines against Middle East respiratory syndrome coronavirus for humans and camels
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) is caused by a novel betacoronavirus that was isolated in late 2012 in Saudi Arabia. The viral infections have been reported in more than 1700 humans, ranging from asymptomatic or mild cases to severe pneumonia with a mortality rate of 40%. It is well documented now that dromedary camels contract the infection and shed the virus without notable symptoms, and such animals had been infected by at least the early 1980s. The mechanism of camel to human transmission is still not clear, but several primary cases have been associated with camel contact. There is no approved antiviral drug or vaccine against MERS-CoV despite the active research in this area. Vaccine candidates have been developed using various platforms and regimens and have been tested in several animal models. Here, this article reviews the published studies on MERS-CoV vaccines with more focus on vaccines tested in large animals, including camels. It is foreseeable that the 1-health approach could be the best way of tackling the MERS-CoV endemic in the Arabian Peninsula, by using the mass vaccination of camels in the affected areas to block camel to human transmission. Camel vaccines can be developed in a faster time with fewer regulations and lower costs and could clear this virus from the Arabian Peninsula if accompanied by efficient public health measures.
Keywords: MERS coronavirus vaccine; Middle East Respiratory Syndrome; camel vaccine.
Copyright © 2016 John Wiley & Sons, Ltd.
Figures

Similar articles
-
Cross-sectional study of MERS-CoV-specific RNA and antibodies in animals that have had contact with MERS patients in Saudi Arabia.J Infect Public Health. 2018 May-Jun;11(3):331-338. doi: 10.1016/j.jiph.2017.09.022. Epub 2017 Oct 6. J Infect Public Health. 2018. PMID: 28993171 Free PMC article.
-
Middle East respiratory syndrome coronavirus (MERS-CoV): animal to human interaction.Pathog Glob Health. 2015;109(8):354-62. doi: 10.1080/20477724.2015.1122852. Pathog Glob Health. 2015. PMID: 26924345 Free PMC article. Review.
-
High Prevalence of MERS-CoV Infection in Camel Workers in Saudi Arabia.mBio. 2018 Oct 30;9(5):e01985-18. doi: 10.1128/mBio.01985-18. mBio. 2018. PMID: 30377284 Free PMC article.
-
Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.J Virol. 2016 Dec 16;91(1):e01651-16. doi: 10.1128/JVI.01651-16. Print 2017 Jan 1. J Virol. 2016. PMID: 27795425 Free PMC article.
-
Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches.Curr Opin Virol. 2017 Apr;23:49-58. doi: 10.1016/j.coviro.2017.03.007. Epub 2017 Apr 13. Curr Opin Virol. 2017. PMID: 28412285 Free PMC article. Review.
Cited by
-
One Health in the context of coronavirus outbreaks: A systematic literature review.One Health. 2020 Dec;10:100170. doi: 10.1016/j.onehlt.2020.100170. Epub 2020 Sep 26. One Health. 2020. PMID: 33015306 Free PMC article. Review.
-
ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.Vaccine. 2017 Jun 27;35(30):3780-3788. doi: 10.1016/j.vaccine.2017.05.032. Epub 2017 Jun 1. Vaccine. 2017. PMID: 28579232 Free PMC article.
-
A Mini Review of the Zoonotic Threat Potential of Influenza Viruses, Coronaviruses, Adenoviruses, and Enteroviruses.Front Public Health. 2018 Apr 9;6:104. doi: 10.3389/fpubh.2018.00104. eCollection 2018. Front Public Health. 2018. PMID: 29686984 Free PMC article. Review.
-
Messenger Ribonucleic Acid (mRNA)-Based Universal Vaccines: Engineering Broad-Spectrum Immunity Against Future Pandemics.Cureus. 2025 May 26;17(5):e84821. doi: 10.7759/cureus.84821. eCollection 2025 May. Cureus. 2025. PMID: 40420966 Free PMC article. Review.
-
Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial.Lancet Microbe. 2022 Jan;3(1):e11-e20. doi: 10.1016/S2666-5247(21)00193-2. Epub 2021 Nov 3. Lancet Microbe. 2022. PMID: 34751259 Free PMC article. Clinical Trial.
References
-
- Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–1820. - PubMed
-
- World Health Organization . Middle East respiratory syndrome coronavirus (MERS‐CoV) [Internet]. Geneva: World Health Organization; 2016 Sep [cited 2016 Sep 01]. Available from: http://www.who.int/emergencies/mers-cov/en/
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources